Charles P E, Noel R, Massin F, Guy J, Bollaert P E, Quenot J P, Gibot S
Service de Réanimation Médicale, Hôpital Bocage Central, C.H.U. Dijon, 14 rue Gaffarel, 21000, Dijon, France.
Medical Intensive Care Unit, Hôpital Bocage Central, Centre Hospitalier et Universitaire de Dijon, 14, rue Gaffarel, 21000, Dijon, France.
BMC Infect Dis. 2016 Oct 12;16(1):559. doi: 10.1186/s12879-016-1893-4.
Among septic patients admitted to the intensive care unit (ICU), early recognition of those with the highest risk of death is of paramount importance. Since clinical judgment is sometimes uncertain biomarkers could provide additional information likely to guide critical illness management. We evaluated the prognostic value of soluble Triggering Receptor Expressed by Myeloid cells 1 (sTREM-1), procalcitonin (PCT) and leucocyte surface expression of CD64.
This was a prospective cohort study, which included 190 septic patient admitted to the ICU in two hospitals. Blood samples for biomarker measurements were obtained upon admission and thereafter. The Simplified Acute Physiology Score (SAPS) II and the Sequential Organ Failure Assessment (SOFA) score were calculated. The primary outcome was all-cause death in the ICU.
The mortality rate reached 25.8 %. The best predictive value of the three biomarkers was obtained with baseline sTREM-1, although clinical scores outperformed this. Accuracy was greater in patients without prior exposure to antibiotics and in those with proven bacterial infection. Adding sTREM-1 levels to SAPS II increased its specificity to 98 %. The soluble TREM-1 level, core temperature and SAPS II value were the only independent predictors of death after adjustment for potential confounders. A decrease in sTREM-1 with time was also more pronounced in survivors than in non-survivors.
sTREM-1 was found to be the best prognostic biomarker among those tested. Both baseline values and variations with time seemed relevant. Although SAPS II outperformed sTREM-1 regarding the prediction of ICU survival, the biomarker could provide additional information.
在入住重症监护病房(ICU)的脓毒症患者中,早期识别出死亡风险最高的患者至关重要。由于临床判断有时并不确定,生物标志物可为指导危重病管理提供额外信息。我们评估了可溶性髓系细胞触发受体1(sTREM-1)、降钙素原(PCT)和白细胞表面CD64表达的预后价值。
这是一项前瞻性队列研究,纳入了两家医院190例入住ICU的脓毒症患者。入院时及之后采集用于生物标志物检测的血样。计算简化急性生理学评分(SAPS)II和序贯器官衰竭评估(SOFA)评分。主要结局是ICU内的全因死亡。
死亡率达25.8%。三种生物标志物中,基线sTREM-1的预测价值最佳,不过临床评分表现更优。在未预先使用抗生素的患者和已证实细菌感染的患者中,准确性更高。将sTREM-1水平加入SAPS II后,其特异性提高至98%。在对潜在混杂因素进行校正后,可溶性TREM-1水平、核心体温和SAPS II值是仅有的死亡独立预测因素。存活者中sTREM-1随时间的下降也比非存活者更明显。
在所检测的生物标志物中,sTREM-1是最佳的预后生物标志物。基线值和随时间的变化似乎都具有相关性。虽然在预测ICU存活方面SAPS II优于sTREM-1,但该生物标志物可提供额外信息。